Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
For the full year, revenue was USD 186.37 million compared to USD 77.06 million a year ago. Net loss was USD 160.91 million compared to USD 135.67 million a year ago. Basic loss per share from continuing operations was USD 3.94 compared to USD 4.01 a year ago. Diluted loss per share from continuing operations was USD 3.94 compared to USD 4.01 a year ago.